Puma Biotechnology Inc | search
Click here to view Puma Biotechnology Inc news from 60+ newspapers.
Bookmark or Share- Puma Biotechnology Inc (PBYI) Reports Q1 Financial Results, Misses ...Puma Biotechnology Inc (NASDAQ:PBYI) disclosed its financial results for the first quarter ended March 31, 2024, through its recent 8-K filing. The company reported a net loss of $4.8 million, or ...
- Puma Biotechnology, Inc. - Puma Biotechnology Announces Phase II ...December 11, 2023. LOS ANGELES-- (BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), announced the design of the Phase II trial of alisertib for the treatment of patients with HER2-negative, hormone receptor-positive metastatic breast cancer (PUMA-ALI-1201). Based on the Company’s interactions ...
- Puma BiotechnologyPuma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357 in 2011.
- Puma Biotechnology, Inc. - Puma Biotechnology Announces Exclusive ...Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.
- Puma Biotechnology, Inc. - Puma Biotechnology Announces FDA Clearance ...Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.
More
